GSK gains a PRV alongside FDA approval for recurring malaria treatment
After two decades of R&D work, GSK has scored an FDA OK for its recurring malaria med, earning a valuable priority review voucher along the way.
Krintafel (tafenoquine) has been approved to prevent the relapse of a type of malaria induced by the Plasmodium vivax parasite, which can not only cause an acute malaria episode at the first mosquito bite but also lie dormant in the liver and reactivates occasionally, causing relapses.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
